T
42.15
11.45 (37.30%)
| Previous Close | 30.70 |
| Open | 41.53 |
| Volume | 12,066,897 |
| Avg. Volume (3M) | 1,519,868 |
| Market Cap | 3,887,981,568 |
| Price / Earnings (Forward) | 44.25 |
| Price / Sales | 5.26 |
| Price / Book | 23.30 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | -82.88% |
| Operating Margin (TTM) | -52.21% |
| Diluted EPS (TTM) | -2.78 |
| Quarterly Revenue Growth (YOY) | 97.50% |
| Total Debt/Equity (MRQ) | 1,220.07% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | -160.66 M |
| Levered Free Cash Flow (TTM) | -239.23 M |
| Return on Assets (TTM) | -23.21% |
| Return on Equity (TTM) | -422.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Travere Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.1
| Analyst Consensus | -3.5 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -1.10 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 113.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Janus Henderson Group Plc | 31 Dec 2025 | 10,511,166 |
| Armistice Capital, Llc | 31 Dec 2025 | 3,763,891 |
| Renaissance Technologies Llc | 31 Dec 2025 | 2,246,779 |
| Rock Springs Capital Management Lp | 31 Dec 2025 | 2,210,322 |
| Bank Of America Corp /De/ | 31 Dec 2025 | 1,850,355 |
| Stephens Investment Management Group Llc | 31 Dec 2025 | 1,721,623 |
| 52 Weeks Range | ||
| Median | 38.00 (-9.85%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 06 Feb 2026 | 38.00 (-9.85%) | Hold | 29.71 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DUBE ERIC M | - | 31.42 | -60,000 | -1,885,200 |
| REED ELIZABETH E | - | 31.42 | -10,000 | -314,200 |
| Aggregate Net Quantity | -70,000 | |||
| Aggregate Net Value ($) | -2,199,400 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 31.42 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| REED ELIZABETH E | Officer | 01 Apr 2026 | Automatic sell (-) | 10,000 | 31.42 | 314,200 |
| REED ELIZABETH E | Officer | 01 Apr 2026 | Option execute | 10,000 | - | - |
| DUBE ERIC M | Officer | 01 Apr 2026 | Automatic sell (-) | 60,000 | 31.42 | 1,885,200 |
| DUBE ERIC M | Officer | 01 Apr 2026 | Option execute | 60,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |